Candel Therapeutics Inc. (CADL)

Market Closed

2 Jun, 20:00

NASDAQ (NMS)

5. 59

+0.14

+2.57%

272.06M Market Cap

- P/E Ratio

0% Div Yield

613,458 Volume

-0.91 Eps

$ 5.45

Previous Close

Day Range

5.37 5.73

Year Range

3.79 14.6

Summary

CADL closed yesterday higher at $5.59, an increase of 2.57% from Friday's close, completing a monthly decrease of -2.44% or $0.14. Over the past 12 months, CADL stock lost -34.7%.

CADL is not paying dividends to its shareholders.

The last earnings report, released on May 13, 2025, exceeded the consensus estimates by 0.1%. On average, the company has fell short of earnings expectations by -0.21%, based on the last three reports.

The stock of the company had never split.

The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

Want to track CADL and more in your Portfolio? 🎯

Get Started For Free

Overview
Earnings
News

CADL Chart

Loading, please wait...

Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 285.3% in Candel Therapeutics (CADL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks | 1 day ago

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer

Candel stock rises as FDA grants RMAT tag to CAN-2409 after phase III success in prostate cancer. BLA submission is planned at the end of 2026.

Zacks | 5 days ago

Candel Therapeutics get FDA's RMAT designation for prostate cancer therapy

Candel Therapeutics Inc (NASDAQ:CADL) said on Wednesday the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead immunotherapy candidate, CAN-2409, for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease. The RMAT designation is intended to expedite the development and review of regenerative therapies for serious conditions where preliminary evidence suggests the drug may address unmet medical needs.

Proactiveinvestors | 6 days ago

Candel Therapeutics Inc. (CADL) FAQ

What is the stock price today?

The current price is $5.59.

On which exchange is it traded?

Candel Therapeutics Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is CADL.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 272.06M.

Has Candel Therapeutics Inc. ever had a stock split?

No, there has never been a stock split.

Candel Therapeutics Inc. Profile

Biotechnology Industry	Healthcare Sector	Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. CEO	NASDAQ (NMS) Exchange	137404109 Cusip
US Country	38 Employees	- Last Dividend	- Last Split	27 Jul 2021 IPO Date

Overview

Candel Therapeutics, Inc. is a pioneering clinical-stage biopharmaceutical company rooted in the discovery and development of novel immunotherapies aimed at treating cancer patients. With a focus on leveraging innovative technologies and scientific advances, Candel Therapeutics is committed to achieving breakthroughs in cancer treatment. Since its inception in 2003 under the name Advantagene, Inc., the company has undergone a significant evolution, culminating in a name change to Candel Therapeutics, Inc. in November 2020. Headquartered in Needham, Massachusetts, the organization continues to push the boundaries of cancer therapy with its diverse pipeline of drug candidates and proprietary discovery platforms.

Products and Services

CAN-2409

Currently under Phase II clinical trials for pancreatic cancer, Phase III for prostate cancer, and Phase II for lung cancer, CAN-2409 is a promising candidate in Candel's pipeline, showing potential across multiple cancer types. Additionally, it has completed Phase Ib/II trials for high-grade glioma, emphasizing its versatility in the fight against cancer.

CAN-3110

Aimed at targeting recurrent high-grade glioma, CAN-3110 is undergoing Phase I clinical trials. This exploration signifies Candel's dedication to addressing some of the most challenging and aggressive forms of brain cancer, highlighting their commitment to research and development in oncology.

enLIGHTEN Discovery Platform

An innovative, systematic, iterative HSV-based discovery platform, the enLIGHTEN Discovery Platform is at the cornerstone of Candel Therapeutics' efforts to revolutionize cancer treatment. By leveraging human biology and advanced analytics, it enables the creation of new viral immunotherapies designed to combat solid tumors, embodying Candel's pioneering approach to cancer research and therapy.

Contact Information

Address: 117 Kendrick Street

Phone: 617 916 5445

Website: https://www.candeltx.com

Affiliate Program About Report a Bug Terms Privacy Help Contact Us